Best Clinical Endpoints That Likely Induce Worse Prognosis in Interstitial Lung Diseases

Investigation of the Impact of Clinical Outcomes on Disease Progression and Prognosis in Patients With Interstitial Lung Diseases

This prospective cohort study will investigate whether progression of the interstitial lung diseases is related to specific clinical endpoints and their changes over time. Longitudinal data of patients will be compared to an age-matched control group during a follow-up of at least two years.

Inclusion Criteria:

1. Patients with interstitial lung disease:

   • Age between 40 and 75 years old upon inclusion;
   • Diagnosis of interstitial lung disease;
   • Clinical stability for at least 4 weeks prior to inclusion;
   • Absence of any comorbidity that interferes with the performance of tests;

2. Age-matched control group:

   • Age between 40 and 75 years old upon inclusion;
   • Absence of any comorbidity that interferes with the performance of tests;

Exclusion Criteria (both groups):

• Participants that present severe or unstable cardiac disease identified during the cardiopulmonary exercise testing;
• Participants with cognitive deficit that interfere with any of the tests;